Guardant360 is the leading liquid biopsy solution on the market with uncomparable validation data. Guardant360 covers all somatic guideline-recommended genomic biomarkers for advanced solid tumors (SNV, fusions, copy number, indels in 70 genes). Digital sequencing analysis enables near perfect single-molecule analytical sensitivity and 99.9999% specificity, the highest of any NGS method. Results provided in 14 days.
Validation of Guardant360 was published in PLOS and can be downloaded here.Available now for cancer centers in the Nordics! For additional details, pricing and availability, contact us at: firstname.lastname@example.org